Pergamon

SCIENCE DIRECT®

Bioorganic & Medicinal Chemistry Letters 13 (2003) 4521

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Erratum

Erratum to "Aryloxazolidinediones: Identification of Potent Orally Active PPAR Dual α/γ Agonists" [Bioorg. Med. Chem. Lett. 13 (2003) 3541]☆

Ranjit C. Desai,[a,*] Dominick F. Gratale,[a] Wei Han,[a] Hiroo Koyama,[a] Edward Metzger,[a] Victoria K. Lombardo,[a] Karen L. MacNaul,[b] Thomas W. Doebber,[b] Joel P. Berger,[b] Kwan Leung,[c] Ronald Franklin,[c] David E. Moller,[b] James V. Heck[a] and Soumya P. Sahoo[a,*]

[a]*Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA*
[b]*Department of Metabolic Disorders, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA*
[c]*Department of Drug Metabolism, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA*

The Publisher regrets that, owing to a publishing error, the incorrect structure for compound **11** appeared in Table 1 of the above article. The correct table appears below.

Table 1. In vitro human PPAR activities of compounds **1**–**11**



Compd	R	Binding IC_{50} (μM)[13]			Transactivation EC_{50} (μM)[10]		
		α	δ	γ	α	δ	γ
1		0.028	> 50	0.057	0.026	> 3	0.014
2		1.4	> 50	0.037	0.035	> 3	0.039
3		0.21	> 50	0.085	ND	ND	ND
4		0.042	0.92	0.063	ND	ND	ND
5		0.09	0.17	0.019	> 3	> 3	0.167
6		> 10	> 50	0.144	> 3	> 3	0.051
7		0.037	0.14	0.03	ND	ND	ND
8		0.12	> 50	0.064	0.13	> 3	0.11
9		0.062	> 50	0.15	0.17	> 3	0.21
10		0.046	> 50	0.059	0.076	> 3	0.08
11		0.08	> 5	0.34	0.053	> 3	0.081

☆DOI of original article: 10.1016/S0960-894X(03)00785-6
*Corresponding author. Tel.: +1-732-594-3923; fax: +1-732-594-9556; e-mail: ranjit_desai@merck.com

0960-894X/$ - see front matter
doi:10.1016/j.bmcl.2003.10.001